KaloBios Pharmaceuticals (KBIO) announced the pricing of its previously announced IPO of 8,750,000 shares of common stock at a price to the public of $8.00 per share, less underwriting discounts and commissions. KaloBios has granted the underwriters a 30-day option to purchase up to 1,312,500 additional shares of common stock at the same price to cover over-allotments, if any.